{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T17:02:56Z","timestamp":1777482176125,"version":"3.51.4"},"reference-count":20,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"published-print":{"date-parts":[[2018,11]]},"abstract":"\n Objective:<\/jats:title>\n To analyze the expression of micro-RNA 143 (miRNA-143) in the patients with pancreatic cancer and to explore the influence of overexpression of miRNA-143 on pancreatic cancer cells.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n Twenty-five patients with pancreatic cancer that received treatment in their hospital were included in this study. Pancreatic cancer tissues of the patients were surgically removed, and cancer-adjacent tissues were taken for control. Semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) was used to detect the expressions of miRNA-143 and its target gene Kirsten rat sarcoma (KRAS) in pancreatic cancer tissues and cancer-adjacent tissues. Western blot test was conducted to detect the expression of KRAS in pancreatic cancer tissues. Clinicopathologic data of patients were recorded in detail, and the analysis on the correlation of these data with the expression of miRNA-143 in pancreatic cancer tissues was conducted. Pancreatic cancer cell line (PANC-1) was transfected with plasmid for overexpression of miRNA-143, and the influences of miRNA-143 on the apoptosis, migration ability, and invasion ability of the cells were verified by flow cytometry, cell scratch experiment, and Transwell experiment.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n The results of semiquantitative RT-PCR showed that there were significantly lower expression of miRNA-143 (\n p<\/jats:italic>\n \u2009<\u20090.01) and remarkably higher expressions of KRAS gene and KRAS protein (\n p<\/jats:italic>\n \u2009<\u20090.01) in pancreatic cancer tissues compared with cancer-adjacent tissues. The expression of miRNA-143 had no correlation with the patient's age and gender, but was closely related to the tumor size, clinical staging, and metastasis of lymph nodes. The detection with flow cytometry showed that cell apoptosis was significantly increased by overexpression of miRNA-143 in PANC-1 (\n p<\/jats:italic>\n \u2009<\u20090.01). The result of cell scratch experiment indicated that the migration ability of PANC-1 was reduced significantly by overexpression of miRNA-143 (\n p<\/jats:italic>\n \u2009<\u20090.01) and that of Transwell experiment manifested that the invasion ability of PANC-1 was decreased significantly by overexpression of miRNA-143 (\n p<\/jats:italic>\n \u2009<\u20090.01).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n The expression of miRNA-143 in pancreatic cancer tissues is significantly decreased. MiRNA-143 can promote cell apoptosis and regulate the process of pancreatic cancer by inhibiting the migration and invasion of pancreatic cancer cells.<\/jats:p>\n <\/jats:sec>","DOI":"10.1089\/cbr.2018.2500","type":"journal-article","created":{"date-parts":[[2018,7,13]],"date-time":"2018-07-13T15:58:12Z","timestamp":1531497492000},"page":"373-379","source":"Crossref","is-referenced-by-count":14,"title":["Expression of miRNA-143 in Pancreatic Cancer and Its Clinical Significance"],"prefix":"10.1177","volume":"33","author":[{"given":"Bo","family":"Xu","sequence":"first","affiliation":[{"name":"The First People's Hospital of Neijiang","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[{"name":"The First People's Hospital of Neijiang","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Xiang","sequence":"additional","affiliation":[{"name":"The First People's Hospital of Neijiang","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunhai","family":"Liu","sequence":"additional","affiliation":[{"name":"The First People's Hospital of Neijiang","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pingyong","family":"Zhong","sequence":"additional","affiliation":[{"name":"The First People's Hospital of Neijiang","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Xie","sequence":"additional","affiliation":[{"name":"The First People's Hospital of Neijiang","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tinggang","family":"Mou","sequence":"additional","affiliation":[{"name":"The First People's Hospital of Neijiang","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Lai","sequence":"additional","affiliation":[{"name":"The First People's Hospital of Neijiang","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,11,2]]},"reference":[{"key":"e_1_3_2_2_2","first-page":"554","article-title":"Current status and progress of pancreatic cancer in China","volume":"14","author":"Lin Q-J","year":"2015","unstructured":"Lin Q-J, , Yang F, , Jin C, et al. Current status and progress of pancreatic cancer in China. World J Gastroenterol, 2015; 14:554.","journal-title":"World J Gastroenterol"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-016-0497-z"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i44.7930"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-016-0301-7"},{"key":"e_1_3_2_6_2","first-page":"2577","article-title":"PancPRO: Risk assessment for individuals with a family history of pancreatic cancer","volume":"8","author":"Wang X","year":"2016","unstructured":"Wang X, , Gong Y, , Wang D, et al. PancPRO: Risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol, 2016; 8:2577.","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_7_2","first-page":"285","article-title":"Classifying pancreatic cancer using gene expression profiling","volume":"19","author":"Ayars M","year":"2016","unstructured":"Ayars M, , Goggins M. Classifying pancreatic cancer using gene expression profiling. Nat Rev Gastroenterol Hepatol, 2016; 19:285.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"e_1_3_2_8_2","first-page":"266","article-title":"Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo","volume":"30","author":"Chien W","year":"2014","unstructured":"Chien W, , Lee DH, , Zheng Y, et al. Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo. Mol Carcinog, 2014; 30:266.","journal-title":"Mol Carcinog"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2972"},{"key":"e_1_3_2_10_2","first-page":"487","article-title":"The Evi1, microRNA-143, K-Ras axis in colon cancer","volume":"21","author":"Gao J-S","year":"2015","unstructured":"Gao J-S, , Zhang Y, , Tang X, et al. The Evi1, microRNA-143, K-Ras axis in colon cancer. FEBS Lett, 2015; 21:487.","journal-title":"FEBS Lett"},{"key":"e_1_3_2_11_2","first-page":"713","article-title":"An enterovirus-like RNA construct for colon cancer suicide gene therapy","volume":"34","author":"Rasekhian M","year":"2014","unstructured":"Rasekhian M, , Teimoori-Toolabi L, , Amini S, et al. An enterovirus-like RNA construct for colon cancer suicide gene therapy. Invest New Drugs, 2014; 34:713.","journal-title":"Invest New Drugs"},{"key":"e_1_3_2_12_2","first-page":"577","article-title":"MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer","volume":"18","author":"Pichler M","year":"2009","unstructured":"Pichler M, , Ress AL, , Winter E, et al. MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. Br J Cancer, 2009; 18:577.","journal-title":"Br J Cancer"},{"key":"e_1_3_2_13_2","first-page":"7591","article-title":"Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells","volume":"6","author":"Nalls D","year":"2014","unstructured":"Nalls D, , Tang S-N, , Rodova M, et al. Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS One, 2014; 6:7591.","journal-title":"PLoS One"},{"key":"e_1_3_2_14_2","first-page":"435","article-title":"Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer","volume":"8","author":"Castellano G","year":"2016","unstructured":"Castellano G, , Melchiorre R, , Loverre A. Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer. Biomed Res Int, 2016; 8:435.","journal-title":"Biomed Res Int"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-443"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-11-23"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.892940"},{"key":"e_1_3_2_18_2","first-page":"25","article-title":"Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer","volume":"53","author":"Winter E","year":"2012","unstructured":"Winter E, , Stotz M, , Eberhard K, et al. Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer. Br J Cancer, 2012; 53:25.","journal-title":"Br J Cancer"},{"key":"e_1_3_2_19_2","first-page":"266","article-title":"Targeting KRAS oncogene in colon cancer cells with 7-carboxylate indolo[3,2-b]quinoline tri-alkylamine derivatives","volume":"30","author":"Brito H","year":"2014","unstructured":"Brito H, , Martins AC, , Lavrado J, et al. Targeting KRAS oncogene in colon cancer cells with 7-carboxylate indolo[3,2-b]quinoline tri-alkylamine derivatives. J Biol Chem, 2014; 30:266.","journal-title":"J Biol Chem"},{"key":"e_1_3_2_20_2","first-page":"97","article-title":"miR-143 and miR-145 are down-regulated in ulcerative colitis: Putative regulators of inflammation and protooncogenes","volume":"20","author":"Pekow JR","year":"2013","unstructured":"Pekow JR, , Dougherty U, , Mustafi R, et al. miR-143 and miR-145 are down-regulated in ulcerative colitis: Putative regulators of inflammation and protooncogenes. Mol Cell, 2013; 20:97.","journal-title":"Mol Cell"},{"key":"e_1_3_2_21_2","first-page":"328","article-title":"miR-143 overexpression impairs growth of human colon carcinoma xenografts in mice with induction of apoptosis and inhibition of proliferation","volume":"24","author":"Borralho PM","year":"2014","unstructured":"Borralho PM, , Sim\u00f5es AES, , Gomes SE. miR-143 overexpression impairs growth of human colon carcinoma xenografts in mice with induction of apoptosis and inhibition of proliferation. J Clin Invest, 2014; 24:328.","journal-title":"J Clin Invest"}],"container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cbr.2018.2500","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2018.2500","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2018.2500","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:14:57Z","timestamp":1777385697000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cbr.2018.2500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1089\/cbr.2018.2500"],"URL":"https:\/\/doi.org\/10.1089\/cbr.2018.2500","relation":{},"ISSN":["1084-9785","1557-8852"],"issn-type":[{"value":"1084-9785","type":"print"},{"value":"1557-8852","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}